Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 19/20 | 1.00 |
| ▸ | KDR | P35968 | 12/20 | 1.00 |
| ▸ | CSK | P41240 | 4/20 | 0.69 |
| ▸ | EGFR | P00533 | 2/20 | 0.69 |
| ▸ | LCK | P06239 | 2/20 | 0.69 |
| ▸ | YES1 | P07947 | 2/20 | 0.69 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.69 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.69 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.66 |
| ▸ | PKMYT1 | Q99640 | 2/20 | 0.66 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.66 |
| ▸ | GAK | O14976 | 1/20 | 0.66 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.66 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.66 |
| ▸ | STK10 | O94804 | 1/20 | 0.66 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.66 |
| ▸ | ABL1 | P00519 | 1/20 | 0.66 |
| ▸ | FYN | P06241 | 1/20 | 0.66 |
| ▸ | LYN | P07948 | 1/20 | 0.66 |
| ▸ | RET | P07949 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3202847 | 0.85 | SRC (1.00) | SRCKDRCSKEGFRLCK | |
| SCHEMBL3206728 | 0.84 | SRC (0.99) | SRCKDRCSKEGFRLCK | |
| SCHEMBL3192019 | 0.82 | SRC (0.90) | SRCKDRCSKEGFRLCK | |
| SCHEMBL3205977 | 0.81 | SRC (1.00) | SRCKDRCSKEGFRLCK | |
| SCHEMBL3274654 | 0.81 | SRC (0.99) | SRCKDRCSKEGFRLCK | |
| Saracatinib SCHEMBL41547 | 0.80 | SRC (1.00) | SRCKDRCSKEGFRLCK | |
| Saracatinib SCHEMBL29380648 | 0.80 | SRC (1.00) | SRCKDRCSKEGFRLCK | |
| Saracatinib SCHEMBL29357263 | 0.80 | SRC (1.00) | SRCKDRCSKEGFRLCK | |
| Saracatinib SCHEMBL29487213 | 0.80 | SRC (1.00) | SRCKDRCSKEGFRLCK | |
| Saracatinib SCHEMBL4255230 | 0.79 | SRC (0.99) | SRCKDRCSKEGFRLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100280042-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF TUMOURS | HENNEQUIN LAURENT FRANCOIS ANDRE | 2010-11-04 | — | — | US | disclosed |
| US-7696214-B2 | Quinazoline derivatives for the treatment of tumours | ASTRAZENECA AB (SE) | 2010-04-13 | — | — | US | disclosed |
| US-7160891-B2 | Quinazoline derivatives for the treatment of T cell mediated diseases | ASTRAZENECA AB (SE) | 2007-01-09 | — | — | US | disclosed |
| US-20060258642-A1 | Quinazoline derivatives for the treatment of tumours | ASTRAZENECA AB | 2006-11-16 | — | — | US | disclosed |
| US-7049438-B2 | Quinazoline derivatives for treatment of tumours | ASTRAZENECA AB (SE) | 2006-05-23 | — | — | US | disclosed |
| EP-1450808-B1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF T CELL MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2005-06-15 | — | — | EP | disclosed |
| US-20050038050-A1 | Quinazoline derivatives for the treatment of t cell mediated diseases | ASTRAZENECA AB (SE) | 2005-02-17 | — | — | US | disclosed |
| US-20040214841-A1 | Quinazoline derivatives for treatment of tumours | ASTRAZENECA AB (SE) | 2004-10-28 | — | — | US | disclosed |
| EP-1292594-B1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF TUMOURS | ASTRAZENECA AB (SE) | 2004-09-01 | — | — | EP | disclosed |
| WO-2001094341-A9 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF TUMOURS | ASTRAZENECA AB (SE) | 2003-04-17 | — | — | WO | disclosed |
| EP-1292594-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF TUMOURS | AstraZeneca AB (SE) | 2003-03-19 | — | — | EP | disclosed |
| WO-2001094341-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF TUMOURS | ASTRAZENECA AB (SE) | 2001-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258642-A1 | Quinazoline derivatives for the treatment of tumours | TPD52L2, NQO2, H1-5 | SRC 1986/4885KDR 2002/4885CSK 963/4885 |
| US-20040214841-A1 | Quinazoline derivatives for treatment of tumours | NQO2, TOP1, TPD52L2 | SRC 1906/4885KDR 1659/4885CSK 580/4885 |
| US-20050038050-A1 | Quinazoline derivatives for the treatment of t cell mediated diseases | CD4, HLA-DRB1, IFNG | SRC 3241/4885KDR 4015/4885CSK 745/4885 |
| US-20100280042-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF TUMOURS | TPD52L2, NQO2, H1-5 | SRC 1986/4885KDR 2002/4885CSK 963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.